News
Eleva Reaches Industrial Production Scale and Prepares for Clinical Development of Factor H
Eleva, a manufacturer of superior biologics, is scaling up its production capacity to 2500 l in state-of-the-art single-use reactors. This will produce sufficient quantities of factor H to cover all three clinical phases.
Eleva Enters Clinical Development of Difficult-To-Express High-Potential Proteins
Eleva, a manufacturer of superior biologics, is entering clinical phases with its own drug candidates, such as immune-regulating factor H, as well as in collaboration with pharmaceutical partners. Its moss-based platform is ideally suited to produce difficult-to-express but therapeutically promising drug candidates.
Eleva secures up to EUR 60 million to advance a drug candidate, appoints new board member
Eleva, a manufacturer of superior biologics, is exploring the potential of one of its drug candidates for first-in-line therapy of Covid-19. The compound, factor H, is part of the complement system, which is believed to affect the severity of the course of Covid-19. Eleva has developed factor H previously for a different indication and taken it through pre-clinical stages.
